BACKGROUND: Children with Down syndrome (DS) are at increased risk of developing acute leukemia and are more prone to acute toxicities. We studied the incidence and severity of chronic health conditions among survivors of childhood leukemia with DS compared with those without DS. METHODS: Chronic health conditions reported by questionnaire were compared between 154 pediatric leukemia survivors with DS and 581 without DS, matched by leukemia, age at diagnosis, race/ethnicity, sex, radiation location and chemotherapy exposure using Cox models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Subjects were selected from 7139 5-year survivors of leukemia in the Childhood Cancer Survivor Study. RESULTS: Risk of at least 1 late onset chronic health condition (grade 1-5) was similar in the DS population compared with the non-DS group (HR, 1.1; 95% CI, 0.7-1.5). Serious chronic health conditions (grade 3-5) were more common in DS survivors (HR, 1.7; 95% CI, 1.1-2.6), as were 3 chronic health conditions (grades 1-5) (HR, 1.7; 95% CI, 1.2-2.4). The 25-year cumulative incidence of any condition (grades 1-5) was 83% for DS survivors and 69% for non-DS survivors. CONCLUSION: Leukemia survivors with DS have therapy-related chronic health conditions comparable to those of similarly treated survivors without DS, with a few notable exceptions: 1) an increased risk of cataracts, hearing loss, and thyroid dysfunction compared with survivors without DS (though these are known risks in the DS population), 2) decreased risk of second cancers, and 3) increased risk of severe or multiple conditions. Practitioners should be aware of these risks during and after therapy. Cancer 2018;124:617-25.
INTRODUCTION
Down syndrome (DS), which is caused by trisomy of chromosome 21, is the most common congenital genetic anomaly, occurring in 1 out of approximately 700 to 1000 live births. 1, 2 The prevalence of DS is increasing, which has been attributed to an increasing incidence of DS and to the fact that more people with DS are living longer, with the current life expectancy exceeding 50 years. [2] [3] [4] Children with DS are at higher risk for developing acute lymphoblastic leukemia (ALL) and acute myelogenous leukemia (AML) compared with children without DS, 5, 6 and those undergoing cancer therapy are at higher risk for prolonged hospitalizations and acute, treatment-related toxicities, such as infections, mucositis, and hyperglycemia. [7] [8] [9] [10] [11] [12] Children and adults with DS without a history of cancer are also known to have a higher risk of certain chronic medical conditions including cataracts, hearing loss, congenital heart abnormalities, and endocrine issues. [13] [14] [15] However, there are minimal data regarding the late sequelae of cancer therapy in children with DS and leukemia.
Because children with DS who are diagnosed with leukemia are at higher risk of acute toxicities, and because many will survive into adulthood-where they are predisposed to chronic conditions-we hypothesized that these children may be at increased risk of chronic health conditions compared with children who have leukemia without DS. To test this hypothesis, we conducted a matched cohort analysis within the Childhood Cancer Survivor Study (CCSS).
PATIENTS AND METHODS

Patients
The CCSS is a retrospective cohort of 24,368 children who were diagnosed before the age of 21 years with a leukemia, lymphoma, central nervous system tumor, Wilms' tumor, neuroblastoma, sarcoma, or bone tumor between 1970 and 1999 at 1 of 27 collaborating institutions in the United States and Canada and who survived at least 5 years after diagnosis. There were 6148 survivors of childhood acute lymphoblastic leukemia (ALL) and 868 survivors of acute myeloid leukemia (AML) within the CCSS cohort. Demographic characteristics and numerous health outcomes were collected from a baseline, selfadministered questionnaire through the fourth follow up survey for survivors diagnosed between 1970 and 1986 and from an initial baseline questionnaire for survivors diagnosed between 1987 and 1999.
Presence of DS was self-reported (by patient or proxy). The non-DS comparison population was selected by stratified random sampling. A desired ratio of 4 controls to 1 case, where possible, were matched for the following characteristics: diagnosis group (type of leukemia: ALL, AML, other), age at diagnosis (to within 1 year), race (white, non-Hispanic vs other), cyclophosphamide equivalent dose (CED; < 8000 vs 8000 mg/m 2 ), anthracycline dose (250 mg/m 2 vs > 250 mg/m 2 ), total body irradiation (yes/no for both ALL and AML) and cranial/spinal/testicular radiation (yes/no for non-AML only). For 130 of the patients with DS, 4 matching non-DS patients were found. Fewer than 4 matches were found for the remaining 24 patients with DS: 17 DS with 3 non-DS, 3 DS with 2 non-DS, and 4 DS with 1 non-DS. There were 3 patients with DS who did not have a non-DS match using these criteria, hence they were excluded from the analysis. Medical record abstraction of treatment-related factors, including chemotherapy information (ie, whether chemotherapy had been given [yes/ no], method of administration, and cumulative dose), occurred at each local institution. All participants provided informed consent and the study procedures were approved by the regulatory boards at all participating institutions. Vital status and cause of death was ascertained as of December 31, 2013 , via linkage to the US National Death Index.
Health Condition Outcomes
The severity grading of chronic health conditions was based on the Common Terminology Criteria for Adverse Events (version 4.03) and included mild (grade 1), moderate (grade 2), severe or disabling (grade 3), lifethreatening (grade 4), or fatal (grade 5) events. 16 A total of 61 different health conditions were scored across all questionnaires. If there was not enough information to distinguish between grades, the lower score was recorded. Onset of a chronic condition was determined based on self-report of age at first occurrence. Equivalent onset dates of the conditions were calculated using the midpoint of the year of the reported age.
Conditions were further summarized across systems (cardiac, endocrine, etc.) using the maximum grade and earliest reported age. Summaries did not include problems with learning/memory or ovarian failure/testicular dysfunction, because these conditions would be expected in patients with DS. Health conditions before the cancer diagnosis or within 5 years of diagnosis were quantified but were not included in the comparative models.
Statistical Analysis
Frequencies for chronic conditions, categorized by time period, were calculated for DS and non-DS leukemia survivors. We used Cox proportional hazard models to calculate hazard ratios (HR) and 95% confidence intervals (CIs) of late chronic medical conditions, comparing DS leukemia survivors with non-DS leukemia survivors. Survivors entered the analysis 5 years after diagnosis and were followed until the earliest chronic condition, death, or last follow-up. Separate univariate models were used for individual conditions and summaries. HRs were not estimable for all chronic conditions due to the low number of events after cohort entry. In additional analyses among only patients with AML or ALL, interactions were tested between group status and diagnosis group (AML/ALL), and separate HR estimates for the diagnosis groups were generated for those outcomes, indicating a significant interaction at a level of 0.10.
Cumulative incidence curves for any grade 1-5 condition and any grade 3-5 condition among patients with DS or without DS were estimated, with death from causes other than a chronic condition as a competing risk. 17 Cumulative incidence was also evaluated for individual health conditions with an adequate number of events (eg, hypothyroidism) and by type of leukemia (ALL, AML). All cumulative incidence curves started at the prevalence at cohort entry (5 years from diagnosis) to illustrate the full burden of conditions in this population and were truncated at 25 years due to the low numbers of survivors still at risk after that point. Survival estimates were generated for DS and non-DS using the Kaplan-Meier estimator, with comparisons between DS and non-DS based on the log-rank test.
Original Article
All analyses, including reported percentages, were weighted to account for undersampling of ALL survivors in the latter recruitment era (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) , with a weight of 1.21 for ALL age 0 or 11-20 years at diagnosis, and a weight of 3.63 for age 1-10 years. AML subjects had a weight of 1. Frequency counts represent unweighted numbers.
RESULTS
In total, 154 survivors of leukemia with DS were matched with 581 leukemia survivors without DS (Table 1 ). Age at last follow-up was evenly distributed, with the majority of (Fig. 1) ; overall survival by leukemia subtype (AML 84% vs ALL 85%) was also similar for children with and without DS (P 5 .39 and .80, respectively). Of 154 survivors with DS, 123 reported a chronic health condition (grade 1-5). The majority (n 5 99 [63.7%]) reported onset before diagnosis or between diagnosis and 5 years after diagnosis, with only 24 (15.9%) reporting onset of new health condition more than 5 years after diagnosis (Table 2 ). Fifty survivors of leukemia with DS reported severe conditions (grade 3-5), with 28 (16.6%) reporting onset before 5 years after diagnosis and 22 (13.8%) more than 5 years after diagnosis.
HRs for any chronic condition (grade 1-5) reported at least 5 years after diagnosis identified no increased risk for DS compared with non-DS survivors (HR, 1.1; 95% CI, 0.7-1.5; P 5 .78) ( Table 2 ). The risk for severe, lifethreatening, disabling, and fatal late chronic health conditions (grade 3-5) was higher for leukemia survivors with DS (HR, 1.7; 95% CI, 1.1-2.6; P 5 .02). The risk for more than 1 health condition was similar for the 2 groups (HR, 1.2; 95% CI, 0.9-1.7, P 5 .24); however, the risk for 3 chronic conditions was greater in patients with DS (HR, 1.7; 95% CI, 1.2-2.4, P 5 .003). HRs comparing DS with non-DS survivors on 14 selected conditions/ organ systems are provided in Table 2 . DS leukemia survivors were at significantly higher risk for hearing loss (HR, 3.4; 95% CI, 1.9-6.0; P < .0001), endocrine effects (HR, 1.9; 95% CI, 1.4-2.6; P 5 .0001) and cataracts (HR, 3.8; 95% CI, 2.2-6.7; P < .0001), but lower risk for second malignant neoplasms (HR, 0.1; 95% CI, 0.0-0.9; P 5 .04) compared with leukemia survivors without DS. Of note, there was no significant difference in the risk of congestive heart disease in survivors of leukemia with and without DS (HR, 1.8; 95% CI, 0.7-4.8; P 5 .23). Additional models tested interactions with diagnosis group (ALL vs AML). Among AML patients, the risk of multiple conditions was significantly higher for DS vs non-DS (2 conditions: HR, 2.4; 95% CI, 1.4-4.0; P 5 .002; 3 conditions: HR, 3.3; 95% CI, 1.9-5.7, P < .0001), whereas for survivors of ALL, the risk for these outcomes was similar between those with and without DS (2 conditions: HR, 0.9; 95% CI, 0.6-1.3; P 5 .53; 3 conditions: HR, 1.2; 95% CI, 0.8-1.9; P 5 .37).
By 25 years after cancer diagnosis, the cumulative incidence of having developed at least 1 chronic health condition was 83% (95% CI, 77%-88%) for DS survivors and 69% (95% CI, 65%-74%) for survivors of leukemia without DS matched for specific treatment exposures (Fig. 2) . These differences were largely attributable to the fact that survivors with DS had an increased prevalence at 5 years (64% vs 34%) compared with those without DS. The cumulative incidence of any grade 3-5 chronic condition by 25 years after diagnosis was 35% (95% CI, 27%-43%) for survivors of leukemia with DS and 22% (95% CI, 18%-25%) for survivors without DS. The cumulative incidence of any chronic condition as well as for any grade 3-5 chronic condition were similar when stratified by leukemia subtype (Supporting Figure 1) . Figure 3 shows the cumulative incidence of 4 selected conditions for which cumulative incidence was higher in survivors of leukemia with DS compared with matched non-DS survivors. Of note, these data suggest most hearing loss occurs within 10 years of diagnosis, whereas new occurrences of cataracts and endocrinopathies continue over time. Secondary malignant neoplasms (SMN) were less common among survivors with DS than survivors without DS, with a cumulative incidence of 6% (95% CI, 4%-9%) among survivors without DS compared with no cases among survivors with DS at 25 years after diagnosis.
DISCUSSION
In this study, we found that survivors of childhood leukemia with and without DS had a similar overall risk of chronic conditions (grade 1-5) occurring more than 5 years after cancer diagnosis. However, survivors with DS were at higher risk of developing more severe (grade 3-5) late chronic conditions, including cataracts, hearing loss, and endocrinopathies, but at lower risk for developing SMNs.
Five-year overall survival for patients with DS and leukemia varies by type of leukemia. Children with DS and AML fare better than children without DS diagnosed with similar AML subtypes (80% vs 35%), yet children with DS and ALL fare worse compared with children without DS diagnosed with ALL (70% vs 90%). [18] [19] [20] [21] [22] [23] AML in DS patients, termed Myeloid Leukemia of DS (ML-DS), is specific to trisomy 21 and is clinically and genetically distinct from AML occurring in non-DS patients. Improved survival in DS patients with AML may be due to an increased sensitivity of their leukemia cells to commonly used AML agents like cytosine Original Article arabinoside. [24] [25] [26] Whether this increased sensitivity could impact other cells and influence risk of late effects is unknown. Children with DS and ALL have fewer favorable biologic features, which presumably contributes to their lower overall survival. 12, 20 Children with DS and ALL may require additional therapy to eradicate their disease, and this could increase their risk for late effects. It is also well established that children with DS diagnosed with leukemia do experience higher rates of certain acute toxicities, including mucositis, metabolic disturbances, sepsis, and pulmonary complications. 27, 28 The increased acute toxicities could suggest this population may be at higher risk of late effects as well. Because survival continues to improve for children with DS diagnosed with leukemia using risk-based therapeutic strategies, understanding the long-term risks becomes more paramount.
Previous reports on late effects in leukemia survivors with DS are sparse. A recent report from the Children's Oncology Group showed that 77% of AML survivors with DS reported at least 1 chronic medical condition compared with 50% of AML patients without DS. 29 A report evaluating late cardiomyopathy in AML patients with and without DS showed no difference in the incidence of this condition. 30 We also identified that children with DS and leukemia do not seem at higher risk for late cardiac conditions than those without DS despite the known increased incidence of cardiovascular malformations. Another study analyzing the occurrence of clinical cardiotoxicity after anthracyclines for patients treated on Pediatric Oncology Group protocols found DS as a risk factor in multivariate analysis. 31 It is possible that in our study, children with DS and underlying cardiac disease may not have survived the required 5 years to be eligible to participate. Other reports of leukemia survivors with DS found that treatment worsened verbal and adaptive function compared with children with DS who did not have leukemia. 32 We did not examine problems with learning and memory, because these are established deficits in individuals with DS.
We know that people with DS without a history of cancer experience higher rates of hospitalizations and higher rates of many of the chronic conditions identified in our study. 33, 34 Hypothyroidism can occur in up to 40% of adults with DS. 35 Mild to severe hearing loss can be seen in nearly 50% of adults with DS. 36 Cataracts are also common in adults with DS. 37 Thus, our findings may simply reflect the natural history of DS. Nonetheless, we cannot exclude the possibility that treatment for childhood leukemia might exacerbate or increase the risk for some of these conditions. 38, 39 Hypotheses of accelerated aging attributable to telomere shortening or cellular senescence have been posited. 40 Regardless, clinicians who care for leukemia survivors with DS should be aware of these medical risks and should take them into consideration when establishing care and follow-up plans.
Children with DS are prone to medical issues that vary with age. 41 For adolescents and young adults with DS, the American Academy of Pediatrics recommends annual examinations including nutritional assessment (including dietary and iron intake assessments), audiology evaluations, thyroid-stimulating hormone monitoring, ophthalmology evaluation every 2-3 years, appropriate cardiac follow-up, neurologic monitoring for myelopathic signs and neurologic dysfunction, and review of comorbidities (eg, obesity and sleep apnea). Young people with DS who have survived childhood leukemia should, at a minimum, follow these recommendations.
The low risk of subsequent cancers noted in this study is of interest. Only 1 case of an SMN was noted, namely an adenocarcinoma in a survivor of ALL with DS occurring 29 years after the original diagnosis. In the treatment-matched cohort without DS, 26 (4.3%) patients developed SMNs. Another large study with good clinical follow-up of ALL survivors found a similar cumulative incidence of 4.2% at 15 years. 42 The lower risk for SMNs may reflect the established fact that children and adults with DS are actually at lower risk of solid tumors compared with the general population. 43 People with DS are at significantly lower risk of breast, lung, and cervical cancer. 44 The lower risk of second cancers in DS survivors may indicate a potential protective effect of 1 or more chromosome 21-localized genes in reducing the risk of secondary cancers. Studies assessing genetic and environmental modifiers that may influence these risks are warranted. How the low rates of certain solid tumors, like breast cancer, should affect cancer screening among survivors of childhood cancer with have been raised. 45 The lack of an available comparison group of individuals with DS without leukemia prevents us from determining whether the chronic conditions are due to DS or the leukemia therapy. The fact that more chronic conditions were present before 5 years from diagnosis suggests that these conditions may be related more to DS than to the cancer therapy. Although all individuals with DS are at risk for vision, hearing, and endocrine conditions, survivors of childhood leukemia with DS may be more prone to or have accelerated onset of these medical conditions. While not feasible within the confines of the CCSS cohort, future studies regarding the relative contributions are warranted.
Although the small population size and self-reported nature of chronic health conditions are also limitations of this study, to our knowledge this is the largest study assessing the potential long-term complications in children with DS and leukemia. The higher proportion of DS survivors with proxy reports by parents provides a potential for bias in the results (84% for DS survivors vs 30% by non-DS survivors); however, previous studies suggest that parents are more likely to 1) worry more about future health and late effects than patients and 2) over-report events 46 ; thus, the bias would likely overestimate the risk of chronic conditions in DS survivors. It is possible that the follow-up for survivors of leukemia with DS may be more rigorous than survivors without DS. Again, this would potentially increase the number of chronic conditions reported in the DS population. The use of a matched comparison cohort reduces potential confounding bias based on diagnosis and treatment-specific factors. Although the matching for radiation exposure was based on location of radiation and was different for AML and ALL, the overall exposure to any radiation was slightly higher among non-DS survivors (23% vs 17%). Thus, the increased risk for multiple conditions in the DS survivors is less likely due to differences in these therapeutic exposures and more likely related to known DS conditions or differences in sensitivity to treatment exposures. Additionally, newer therapy regimens developed in the Children's Oncology Group take into account the unique clinical and biologic features of leukemia in DS patients in an effort to reduce toxicities; hopefully this will reduce any potential added risk of chronic health conditions due to therapy in this population.
In conclusion, this study demonstrates that survivors of leukemia with DS have an overall similar risk of any late complications, but are at higher risk for specific and more severe conditions. The more common lateoccurring medical conditions, cataracts, hearing loss, and thyroid disorders may be solely related to the underlying DS. Regardless, providers who care for this population of patients should be aware of these risks during therapy as they consider treatment options and after therapy as they monitor for late-occurring medical conditions.
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